Research programme: VLA-4 antagonists - Biogen/Merck

Drug Profile

Research programme: VLA-4 antagonists - Biogen/Merck

Latest Information Update: 07 Mar 2007

Price : $50

At a glance

  • Originator Biogen
  • Developer Biogen; Merck & Co
  • Class
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 07 Mar 2007 Discontinued - Preclinical for Asthma in USA (Inhalation)
  • 05 Jul 2000 The former lead compound has been abandoned
  • 05 Jul 2000 Preclinical development for Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top